Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1296Carcinoma, Non-Small-Cell Lung 793Neoplasms 787Colorectal Neoplasms 760Stomach Neoplasms 587Carcinoma, Hepatocellular 581Prostatic Neoplasms 514Lung Neoplasms 466Pancreatic Neoplasms 421Rectal Neoplasms 336Recurrence 314Neoplasm Metastasis 308Leukemia, Myeloid, Acute 293Colonic Neoplasms 283Multiple Myeloma 280Lymphoma 276Esophageal Neoplasms 273Uterine Cervical Neoplasms 272Ovarian Neoplasms 263Melanoma 246Head and Neck Neoplasms 245Precursor Cell Lymphoblastic Leukemia-Lymphoma 210Brain Neoplasms 195Lymphoma, Large B-Cell, Diffuse 187Nasopharyngeal Carcinoma 182Leukemia 173Lymphoma, Non-Hodgkin 171Liver Neoplasms 165Glioblastoma 160Polycystic Ovary Syndrome 157

Interventions

Morphine 1Dexmedetomidine 1Bupivacaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Interventional × Immune System Suppression × Clear all
NCT03024957 2021-01-14

Effect of Intrathecal Morphine, Dexmedetomidine or Both in Combination to Bupivacaine on Immunity

Assiut University

Phase 1/2 Unknown
30 enrolled

Immune System Suppression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡